International Assets Investment Management LLC trimmed its holdings in shares of Progyny, Inc. (NASDAQ:PGNY – Free Report) by 98.4% during the fourth quarter, Holdings Channel reports. The fund owned 2,500 shares of the company’s stock after selling 151,964 shares during the quarter. International Assets Investment Management LLC’s holdings in Progyny were worth $64,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also modified their holdings of the company. Principal Financial Group Inc. increased its position in shares of Progyny by 57.1% during the third quarter. Principal Financial Group Inc. now owns 704,267 shares of the company’s stock worth $15,156,000 after acquiring an additional 256,078 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Progyny by 2.4% during the third quarter. Vanguard Group Inc. now owns 10,106,147 shares of the company’s stock worth $217,484,000 after acquiring an additional 235,513 shares during the last quarter. Intech Investment Management LLC increased its position in shares of Progyny by 336.0% during the third quarter. Intech Investment Management LLC now owns 169,834 shares of the company’s stock worth $3,655,000 after acquiring an additional 130,885 shares during the last quarter. Algert Global LLC increased its position in shares of Progyny by 35.1% during the third quarter. Algert Global LLC now owns 595,805 shares of the company’s stock worth $12,822,000 after acquiring an additional 154,930 shares during the last quarter. Finally, Barclays PLC increased its position in shares of Progyny by 79.2% during the third quarter. Barclays PLC now owns 1,575,470 shares of the company’s stock worth $33,904,000 after acquiring an additional 696,447 shares during the last quarter. 94.93% of the stock is owned by hedge funds and other institutional investors.
Progyny Stock Up 1.7%
Shares of Progyny stock opened at $23.25 on Friday. The firm has a market cap of $1.82 billion, a P/E ratio of 30.19, a P/E/G ratio of 1.24 and a beta of 0.91. Progyny, Inc. has a fifty-two week low of $16.10 and a fifty-two week high of $28.75. The business has a 50-day moving average price of $18.38 and a 200 day moving average price of $21.83.
Insider Buying and Selling
In other Progyny news, EVP Allison Swartz sold 4,657 shares of Progyny stock in a transaction that occurred on Tuesday, March 3rd. The stock was sold at an average price of $17.40, for a total value of $81,031.80. Following the completion of the transaction, the executive vice president directly owned 89,879 shares in the company, valued at $1,563,894.60. The trade was a 4.93% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders sold 7,455 shares of company stock valued at $129,515 in the last three months. Insiders own 9.90% of the company’s stock.
Analyst Upgrades and Downgrades
A number of analysts have recently issued reports on PGNY shares. Canaccord Genuity Group dropped their target price on Progyny from $26.00 to $19.00 and set a “hold” rating on the stock in a research report on Wednesday, March 11th. Weiss Ratings reissued a “hold (c)” rating on shares of Progyny in a report on Friday, March 27th. Truist Financial boosted their price objective on Progyny from $28.00 to $30.00 and gave the company a “buy” rating in a report on Monday, May 11th. Wall Street Zen raised Progyny from a “hold” rating to a “buy” rating in a report on Saturday, April 18th. Finally, KeyCorp lowered their price objective on Progyny from $32.00 to $28.00 and set an “overweight” rating for the company in a report on Monday, March 2nd. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $28.55.
Read Our Latest Research Report on Progyny
Progyny Company Profile
Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.
The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.
Read More
- Five stocks we like better than Progyny
- 3 Stocks to Own If Gas Prices Keep Rising
- 3 Crucial Aerospace Component Makers That Analysts Love
- Alphabet’s Googlebook Brings Gemini AI to PC Hardware
- Peloton Stock Gives Back Gains After Upbeat Earnings Report
Want to see what other hedge funds are holding PGNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Progyny, Inc. (NASDAQ:PGNY – Free Report).
Receive News & Ratings for Progyny Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progyny and related companies with MarketBeat.com's FREE daily email newsletter.
